ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME

Patent metadata

Field	Value
Publication number	US-2018200266-A1
Application number	US-201615744537-A
Country	US
Kind code	A1
Filing date	Jul 13, 2016
Priority date	Jul 14, 2015
Publication date	Jul 19, 2018
Grant date	—

Abstract

[Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor α-inhibiting β partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.

First claim

1 . An estrogen receptor α-inhibiting β partial agonist represented by the following formula (a);

2 . A gynecological disease therapeutic agent comprising the estrogen receptor α inhibiting β partial agonist of claim 1 , a pharmaceutically acceptable salt thereof, or a hydrate of the afore-mentioned as an active ingredient.

3 . The gynecological disease therapeutic agent according to claim 2 , wherein the gynecological disease comprises endometriosis, uterine fibroids, and/or uterus adenomyosis.

Assignees

• Nobelpharma Co Ltd
• Nat Univ Corp Tottori Univ

Inventors

• Nakao Kenichiro
• Harada Tasuku
• Taniguchi Fuminori

Classifications

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61K31/573 Primary

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61P15/02

  for disorders of the vagina · CPC title

• C07J41/0072

  the A ring of the steroid being aromatic · CPC title